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Background: The aim was to assess one-year changes in uncorrected and corrected con-
trast sensitivity (CS) and glare under scotopic conditions after accelerated cross-linking
(CXL) using the 18 mW/cm2 protocol for the treatment of progressive keratoconus and
compare results with unoperated controls.
Methods: In this non-randomised clinical trial, 30 eyes were enrolled in the CXL group
and 30 were assigned to the control group. Scotopic CS at spatial frequencies (SFs) of 0.5,
1.1, 2.2, 3.4, 7.1 and 15 cycles per degree (cpd) were assessed using the MonCv3System
(Metrovision, Pérenchies, France) under scotopic conditions (0.5 lux) at baseline and at
six and 12 months.
Results: The mean ages of the participants in the CXL and control groups were
24.32  5.17 and 30.93  7.43 years, respectively (p < 0.001). After adjusting for age,
changes in uncorrected and corrected CS and glare were similar in the two groups (all
p > 0.05) except for corrected CS at SF 7.1 cpd (1.45  4.31 versus 3.21  4.69 dB,
p = 0.010) and 15 cpd (1.12  4.63 versus 3.03  5.48 dB, p = 0.007), which were
reduced as an effect of CXL. Based on covariate analyses, among corrected CS indices,
corrected CS7.1 and CS15 were related to CXL and their baseline values (all p < 0.050).
Uncorrected CS in all SFs and uncorrected and corrected glare were related to their pre-
operative values (all p < 0.001).
Conclusion: Accelerated CXL can reduce scotopic corrected CS at SFs higher than
7.0 cpd in cases with better baseline values of these parameters. Changes in uncorrected
CS and glare are only a factor of baseline values and the indices reduce in cases with bet-
ter baseline values after one year.
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Loss of contrast sensitivity (CS), as an index
independent of changes in visual acuity
(VA), has been reported in keratoconic
patients in different studies.1–3 In keratoco-
nus, increasing higher order aberrations
(HOAs) have a more deteriorating effect
on CS compared to VA.4 After corneal
cross-linking (CXL), photopic CS improves
as a result of reduced HOAs, especially ver-
tical coma.5,6 Also, it has been shown that
night time halo and driving problems may
reduce after CXL.7
Under low light conditions, the pupil
dilates and HOAs increase and this
increases patients’ troubles, especially when
driving. Therefore, it is important to assess
CS under low light conditions after the
CXL procedure. The recommended road
luminance is 0.3 to 2.0 cd/m2 in Europe
and 0.3 to 1.2 cd/m2 in the United States.8
In Iran, according to the regulations by the
Ministry of Roads and Urban Development,
night time luminous intensity based on traf-
fic volume is two to 12 lux in the streets
and 16 lux in roads with high traffic loads.
Therefore, it seems pertinent to examine
CS under scotopic conditions (0.5 lux) in
keratoconus patients undergoing CXL.
To the best of our knowledge, no previ-
ous study has been done in this regard
and scotopic CS and glare have not been
studied after CXL. The objective of the
present study is to assess CS and glare
under scotopic lighting conditions in a
group of patients undergoing accelerated
CXL (18 mW/cm2, five minutes) and
compare results with a group of unoper-
ated keratoconus patients as controls to
examine the effect of the procedure on
night vision.
METHODS
This prospective non-randomised clinical
trial began in June 2013 at Noor Eye Hospi-
tal, Tehran, Iran. The present report exam-
ines CS and glare in patients with
progressive keratoconus (at least one diop-
tre increase in maximum keratometry
[Kmax], manifest cylinder or manifest
refraction spherical equivalent in the last
12 months) in a group undergoing acceler-
ated CXL (18 mW/cm2, five minutes)
(30 eyes) and a control group receiving no
intervention (30 eyes). The control group
included patients who were simply moni-
tored for one year without any interven-
tion; those who received treatment at any
time were excluded from the study. Inclu-
sion criteria for the CXL group were age
between 15 and 35 years, Kmax less than
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55 D and a minimum central corneal thick-
ness of 400 μm. Exclusion criteria were any
history of ocular surgery or disease other
than keratoconus. Soft and hard contact
lens wearers discontinued using lenses
three days and three weeks, respectively,
before the examinations.
Ethics consideration
The proposal of the study was reviewed
and approved by the Ethics Committee of
Tehran University of Medical Sciences. The
study adhered to the tenets of the Declara-
tion of Helsinki at all stages. Written
informed consent was obtained from all
participants.
Surgical technique
The surgical technique has been described
elsewhere.9 In brief, after local anaesthesia
and removing the central 9.0 mm of the cor-
neal epithelium, the lid speculum was
removed and 0.1 per cent riboflavin in
20 per cent dextran (Streuli Pharmaceuti-
cals, Uznach, Switzerland) was instilled onto
the cornea every three minutes for half an
hour. The cornea was then irradiated at
18 mW/cm2 using the CCL 365 (PESCHKE
Meditrade GmbH, Kiefersfelden, Germany).
After rinsing the corneal surface, a soft band-
age contact lens (Night & Day, Ciba Vision,
Duluth, Minnesota, USA) was placed and a
drop of levofloxacin was instilled. The post-
operative regimen included levofloxacin eye
drops four times daily, betamethasone
0.1 per cent and preservative free artificial
tears as needed. Follow-up examinations
were conducted and the bandage contact
lens was removed after complete re-
epithelialisation was observed. Upon
removal of the lens, levofloxacin was discon-
tinued and betamethasone, four times daily
was continued for another week.
Pre- and post-operative
examinations
Tests for CS and glare were conducted with
and without correction under scotopic con-
ditions (0.5 lux) using the Metrovision
MonCv3 (Metrovision, Pérenchies, France)
at baseline and at six and 12 months after
the procedure and results were compared
between the CXL and control groups. All
baseline and follow-up examinations were
conducted in a clinic room designated for
this purpose by the same optometrist, who
was masked to group allocation.
To adjust lighting of 0.5 lux, entry of sun-
light into the room was completely blocked
and after turning on the MonCv3, room
light intensity was measured using the
Sekonic L-308 DC light meter (Sekonic
Corporation, Tokyo, Japan). Patients were
seated in the room for 10 to 15 minutes
prior to testing to adapt to the lighting
conditions.
Psychophysical CS testing was done using
Metrovision vertical gratings of sine waves
of various spatial frequencies (SFs). With
this method, contrast is gradually increased
until the patient’s subjective response is
received and the result is recorded. After
testing CS at SF of 0.5 (CS0.5), 1.1 (CS1.1),
Study group Baseline Follow-up 12-month
change
p-
value*
6 months 12 months
CS0.5 (dB) Cross-linking 14.91  3.30 16.35  2.35 17.00  1.86 2.04  3.96 0.555
Control 15.75  1.60 16.29  2.37 17.39  2.54 1.69  3.26
CS1.1 (dB) Cross-linking 17.61  3.56 18.83  2.19 19.70  2.64 2.04  4.36 0.139
Control 18.89  2.01 19.39  2.47 20.32  2.52 1.45  2.56
CS2.2 (dB) Cross-linking 19.30  1.69 19.83  2.77 20.39  3.01 1.21  2.59 0.313
Control 20.21  2.51 21.18  2.39 21.79  2.54 1.55  2.77
CS3.4 (dB) Cross-linking 18.48  2.48 18.70  2.36 19.83  2.87 1.29  2.29 0.684
Control 20.07  2.71 20.86  2.81 21.07  2.75 1.00  2.10
CS7.1 (dB) Cross-linking 14.87  3.39 16.48  2.91 16.22  4.19 1.45  4.31 0.010
Control 16.39  4.44 17.39  4.37 19.71  3.39 3.21  4.69
CS15 (dB) Cross-linking 7.39  3.54 8.30  2.91 8.65  4.30 1.12  4.63 0.007
Control 9.04  4.91 9.25  5.03 12.18  3.71 3.03  5.48
*Inter-group comparison of one-year changes using repeated measures analyses of covariance.
Table 1. One-year changes in scotopic corrected contrast sensitivity in cases treated
with accelerated cross-linking compared to untreated cases of progressive keratoconus
Study group Baseline Follow-up 12-month
change
p-
value*
6 months 12 months
CS0.5 (dB) Cross-linking 15.64  1.55 16.07  1.21 16.50  2.77 0.87  1.60 0.273
Control 16.75  0.50 17.25  0.50 16.75  0.96 0.10  1.37
CS1.1 (dB) Cross-linking 16.93  3.43 17.29  2.76 18.07  3.15 0.87  2.53 0.757
Control 18.75  1.26 19.75  2.22 19.50  1.73 0.50  1.43
CS2.2 (dB) Cross-linking 16.50  3.13 16.64  2.98 18.36  3.85 1.43  3.07 0.967
Control 19.00  2.71 20.50  3.42 20.00  2.58 1.00  1.05
CS3.4 (dB) Cross-linking 15.43  4.60 15.21  3.47 16.93  4.71 0.48  3.96 0.475
Control 18.25  4.19 19.75  3.40 20.25  3.30 0.40  2.91
CS7.1 (dB) Cross-linking 13.00  5.70 13.86  4.26 14.21  6.45 0.04  3.73 0.374
Control 14.75  2.75 18.00  4.08 17.75  4.92 0.80  4.18
CS15 (dB) Cross-linking 5.14  3.39 5.43  3.84 7.14  5.71 0.61  4.27 0.701
Control 10.25  2.50 11.00  6.63 10.00  6.78 −0.20  4.41
*Inter-group comparison of one-year changes using repeated measures analyses of covariance.
Table 2. One-year changes in scotopic uncorrected contrast sensitivity in cases treated
with accelerated cross-linking compared to untreated cases of progressive keratoconus
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2.2 (CS2.2), 3.4 (CS3.4), 7.1 (CS7.1) and
15 (CS15) cpd, the device displays the
graph of the CS function and registers CS
at each SF in the dB unit. Testing was done
monocularly at two metres (manufacturer’s
recommended distance).
For testing glare, we used optotypes with
a luminance of 100 cd/m2 on a dark back-
ground while a strong source of white light
(luminance = 200,000 cd/m2) was pro-
jected toward the patient to create glare.
Displayed optotypes were 15 arcmin, which
is equivalent to 0.33 VA. Testing was done
monocularly at 2.5 metres. Different opto-
type arrangements were used for each eye.
The final score was recorded as the per-
centage of correct responses, which was cal-
culated based on the algorithm for each
optotype and the distance from the source
of glare.
Initially, to test the repeatability, 30 eyes
of 30 emmetropic volunteers were exam-
ined twice, 30 to 60 minutes apart. All these
tests were done by the same optometrist in
the same designated room.
Statistical analyses
One-year changes in the CXL group were
compared to the control group using
repeated measures analysis of covariance
(RM ANCOVA). In the analyses, adjust-
ments were made for age and the correla-
tion between fellow eyes for binocular
cases. The level of significance was set
at 0.05.
RESULTS
At the end of one year, 26 eyes in the CXL
group (86.7 per cent) and 30 eyes in the
control group (100.0 per cent) completed
CS and glare tests; 54.4 per cent of patients
in the CXL group and 50.0 per cent of those
in the control group were male. As the study
was non-randomised, baseline parameters
were compared between the two groups.
The mean age of the participants was
24.32  5.17 years in the CXL group and
30.93  7.43 in the control group
(p < 0.001); since the difference was statisti-
cally significant, the effect of age was con-
trolled as a covariate in all analyses. In the
CXL and control groups, baseline Kmax was
46.53  3.31 and 47.24  3.46 D, baseline
Kmin was 43.68  2.67 and 44.56  2.19 D,
baseline distance VA was 0.15  0.16 and
0.13  0.18 logMAR and uncorrected dis-
tance vision (UDV) was 0.45  0.41 and
0.51  0.40 logMAR, respectively (all
p > 0.050). One year after CXL, mean
reduction of Kmax and Kmin was
0.48  0.10 D and 0.02  0.89 D, respec-
tively. Also, VA and UDV improved to
0.12  0.14 logMAR and 0.39  0.36 log-
MAR in these two groups, respectively. CXL-
induced haze was observed in four cases
after one year.
In the repeatability analyses, the within-
subject standard deviation (Sw) was 0.86,
0.75, 0.68, 0.64, 0.80 and 1.48 dB for SF of
0.5 to 15 cpd, respectively, and precision of
measurement (mean difference of two
measurements  1.96 × Sw) was 3.37, 2.96,
2.68, 2.49, 3.15 and 1.00 dB, respectively.
Table 1 compares corrected scotopic CS
and Table 2 compares uncorrected
Figure 1. One-year changes in scotopic corrected (A and B) and uncorrected (C and
D) contrast sensitivity in cases treated with accelerated cross-linking compared to
untreated cases of progressive keratoconus
Figure 2. One-year changes of scotopic corrected contrast sensitivity (CS) in subgroups
with reduced (left) and improved (right) CS after accelerated cross-linking compared
to untreated cases. Changes were statistically significant between the two groups in spa-
tial frequencies of 7.1 and 15 cycles per degree.
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scotopic CS in different SFs between the two
groups. Comparison of changes in different
parameters showed no significant differences
between the two groups (all p > 0.050) except
for corrected CS7.1 (p = 0.010) and corrected
CS15 (p = 0.007). The percentage of subjects
with increase, decrease and stability of cor-
rected CS and uncorrected CS are illustrated
in Figure 1.
RM ANCOVA showed that among cor-
rected CS indices, only corrected CS7.1
and CS15 were correlated to surgery and
baseline values and at both SFs, surgery
lead to reduced CS in cases with better
baseline CS and improved CS in cases with
lower CS (all p < 0.050) (Figure 2). At one
year, uncorrected CS in all SFs were
correlated only to baseline CS (all
p < 0.001) and not surgery (Figure 3).
Also, as demonstrated in Figure 4, uncor-
rected glare and corrected glare had similar
trends over the one year period and surgery had
no significant impact on either parameter (all
p > 0.050). Both parameters were only influ-
enced by baseline values (both p < 0.001); cases
with higher baseline glare showed reduced glare
at one year and vice versa.
DISCUSSION
In this report, we aimed to explore the
effect of accelerated CXL on CS and glare
in scotopic conditions and related factors.
As age can influence scotopic CS, especially
in SFs less than 1.2 cpd, and CS tends to
reduce at older age10 and since the CXL
group in this study was younger than the
control group, age was controlled for in the
analyses, as a confounding factor. After con-
trolling for age, our one-year follow-up
study showed that CXL only affected cor-
rected CS in SFs higher than 7.0 cpd and
reductions were observed only in cases with
a mean baseline scotopic CS more than
16 dB but in those with a lower mean base-
line, CXL led to improved CS. CXL had no
effect on uncorrected CS or on uncorrected
or corrected glare and similar to the control
group, those with better baseline values
showed a reduction, while those with worse
baseline values showed improvement.
Previous studies indicate that HOAs are
reduced at one year after standard
CXL11,12 and tend to remain stable after-
wards in the long-term.6 Also, photopic CS
is improved after surgery.5 Although CS in
normal cases (1.80  0.13 cpd) is better
than in keratoconic patients,1 no informa-
tion is available about CS improvement
after CXL compared to normal eyes.
An important point is how CS and glare
change under low light conditions, when
pupil dilation leads to increased aberra-
tions. In the study by Vinciguerra and
colleagues,13 at one year after CXL, there
was a greater reduction in coma and spheri-
cal aberrations in the 7.0 mm pupil (0.95
and 0.82 μm) compared to the 3.0 mm
pupil (0.32 and 0.09 μm). The change in
coma was not statistically significant though,
and CS changes were not examined.
Reduced contrast in low light conditions is
more pronounced compared to photopic
conditions because rod photoreceptors
require more contrast difference for target
detection compared to cones (20 versus
one per cent).14 Disability glare occurs
under certain conditions, such as driving
in the night. Intraocular light scattering
(straylight), which is an optic phenome-
non independent of neurophysiology,
results in reduced retinal image contrast.15
Therefore, any type of inhomogeneity in
the ocular media can exacerbate the scat-
tering. As a result, a more regular cornea
after CXL is expected to be associated
with improved CS and reduced disability
glare.
As the parameters in our study changed
in different directions, supplementary ana-
lyses were done separately in each group.
In these analyses, we observed that acceler-
ated CXL can cause a reduction in scotopic
Figure 3. One-year changes of scotopic uncorrected contrast sensitivity (CS) in sub-
groups with reduced (left) and improved (right) CS after accelerated cross-linking
compared to untreated cases.
Figure 4. One-year changes of corrected and uncorrected glare in subgroups with reduced
(left) and improved (right) glare after accelerated cross-linking compared to untreated
cases. None of the cases in the control group showed increased uncorrected glare.
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corrected CS in SFs higher than 7.0 cpd in
cases with better baseline values of this
index. This can be due to the stronger
influence of scattering on higher SFs such
as its effect on VA. Mathematically, higher
SFs are closer to VA16 and studies indicate
that cases with VA better than 6/12 can
experience reduced vision after CXL17 and
the reduction in corrected CS at higher SFs
can be in line with the same effect.
A limitation of this study is being non-
randomised and the possibility of unknown
factors influencing results. Overall, we can say
that changes in uncorrected CS and glare in
keratoconic patients and also after accelerated
CXL only depend on baseline values and
there can be improvement in cases with worse
baseline values and vice versa. Changes in cor-
rected glare have the same pattern but
changes in corrected CS at higher SFs were
affected by surgery, such that surgery resulted
in reduced CS in cases with better baseline
values (CS15 >8 dB and CS7.1 >16 dB) and
vice versa.
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